483
Smithfield Bioscience IncSmithfield Bioscience Inc – FDA 483, May 15, 2019
Record Details
An FDA inspection of Smithfield Bioscience Inc in Cincinnati, OH, an API manufacturer, revealed a significant failure to conduct investigations into out-of-specification (OOS) results. The firm repeatedly re-analyzed heparin sodium samples and re-cleaned environmental monitoring areas without proper investigation or management approval. These findings indicate serious deficiencies in the firm's quality control and investigation processes.
View Company Profile
ID · 42c41f9d-137a-4525-a326-4548b89e4eea
Other documents for Smithfield Bioscience Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.